Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Rosenbach

Allergy & Immunology Naples, FL Medical Doctor

NPI 1841268133 CMS profile 356606

2500 Vanderbilt Beach Rd, Ste 1103, Naples, FL 34109

Open in the dashboard

General payments

$141,355

571 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Rosenbach of Naples, FL is reported in the CMS Open Payments database as having received $141,355 across 571 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,091 93
2024 General $10,342 67
2023 General $31,770 84
2022 General $22,042 63
2021 General $10,045 75
2020 General $11,878 68
2019 General $36,187 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Rosenbach
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Kevin Rosenbach were reported at $19,091. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Kevin Rosenbach Allergy & Immunology median Middle half National median
2019 $36,187 $594 $163–$1,512 $163
2020 $11,878 $426 $106–$1,233 $114
2021 $10,045 $638 $157–$1,708 $132
2022 $22,042 $790 $205–$1,961 $149
2023 $31,770 $852 $220–$2,147 $160
2024 $10,342 $865 $203–$2,267 $164
2025 $19,091 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $37,029 67 payments
  2. Shire North American Group Inc $31,265 67 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $27,644 121 payments
  4. Grifols USA, LLC $20,907 33 payments
  5. Pfizer Inc. $8,742 52 payments
  6. Catalyst Pharmaceuticals, Inc. $3,890 17 payments
  7. CSL Behring $2,373 32 payments
  8. Genentech USA, Inc. $1,994 19 payments
  9. Octapharma USA, Inc. $1,740 23 payments
  10. Blueprint Medicines Corporation $1,403 4 payments
  11. Other $4,368 136 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,019 25 payments
  2. Honoraria $31,537 12 payments
  3. Consulting Fee $25,100 46 payments
  4. Travel and Lodging $23,150 39 payments
  5. Food and Beverage $15,539 448 payments
  6. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. CUVITRU $29,199 85 payments
  2. HYQVIA $22,964 91 payments
  3. Xembify $21,041 30 payments
  4. OCTAGAM IMMUNE GLOBULIN (HUMAN) $5,057 22 payments
  5. CUTAQUIG Immunology $3,884 34 payments
  6. Hizentra $2,087 24 payments
  7. Xolair $1,814 15 payments
  8. CUTAQUIG Immunology $1,533 21 payments
  9. AYVAKIT $1,326 2 payments
  10. PANZYGA $755 30 payments
  11. Other $6,353 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,182

Median for Allergy/ Immunology: 449

Drug cost

$1,556,001

Median for Allergy/ Immunology: $169,700

Branded share of claims

31.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 49 $543,807
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 45 $422,969
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 13 $300,947
Cutaquig Immun Glob G(Igg)-Hipp/Maltose Brand 13 $168,005
Cibinqo Abrocitinib Brand 12 $69,346
Epinephrine Generic 49 $13,013
Cromolyn Sodium Generic 19 $8,972
Cevimeline Hcl Generic 16 $5,662
Fluconazole Generic 138 $5,574
Oseltamivir Phosphate Generic 192 $4,659

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$7,181,377

Of which drugs: $6,850,808

Medicare patients

669

Average age 75

Services billed

134,700

467 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 63%
Ischemic heart disease 38%
COPD 29%
Depression 27%
Osteoporosis 27%
Diabetes 22%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (bivigam), 500 mg J1556 Office 78 74,060 $4,298,983
Injection, omalizumab, 5 mg J2357 Office 30 14,431 $430,584
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 43 4,710 $423
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 22 261 $165
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 13 1,536 $114

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $196
$196 — —
Hizentra
  • CSL Behring $129
$129 — —
CUTAQUIG
  • PFIZER INC. $62
  • Octapharma USA, Inc. $50
$112 13 —
XOLAIR
  • Genentech USA, Inc. $73
  • Novartis Pharmaceuticals Corporation $38
$111 — 14,431
Xembify
  • Grifols Shared Services North America, Inc. $56
  • Grifols USA, LLC $24
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

571 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record